Biosensors Market Outlook:
Biosensors Market size was valued at USD 32.21 billion in 2025 and is set to exceed USD 77.66 billion by 2035, registering over 9.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of biosensors is estimated at USD 34.88 billion.
The rising demand for point-of-care diagnostics and continuous monitoring solutions for patients with diabetes, cardiovascular disease (CVD), and cancer is fuelling the market. Thus, the enlarging worldwide patient pool is directly proportionated to the sector’s expansion. On this note, NLM projected the global diabetes prevalence to reach 578.0 million and 700.0 million by 2030 and 2045, respectively. Similarly, the crude occurrence and mortality of CVD around the globe are expected to increase by 90.0% and 73.4% from 2025 to 2050. The number of deaths due to this condition is further poised to surpass 35.6 million by the end of 2050 (NLM). On the other hand, the annual number of new diagnoses and deaths from cancer is predicted to cross 26.0 million and 17.0 million by 2030 (NLM)
This magnifying demography indicates the continuous flow of business in the market throughout the upcoming years. As the economic burden on patients with such chronic conditions rises, the need for a treatment approach with reduced expenses is increasing. To establish this fact, an NLM study calculated the net global expenditure on these residents to attain USD 47.0 trillion by 2030. This is pushing companies to develop solutions that offer faster and more accurate detection and surveillance, where biosensors are clinically proven to establish affordable payers’ pricing for advanced healthcare. Moreover, associated medical devices are eliminating the need for long-term hospitalization and a workforce for monitoring disease progression or drug efficacy to serve this purpose.
